Show Summary Details
Page of

Adjunctive Medicines 

Adjunctive Medicines
Adjunctive Medicines

Harris A. Gelbard

and Stuart A. Lipton

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 July 2020

Antiretroviral drugs are the only therapy currently in general use for the treatment of HIV-associated neurocognitive disorders (HAND), but the treatment response to these agents may be unsatisfactory or short lived. One reason for this unsatisfactory response may be that the pathophysiology of HAND is initiated by the virus but involves a cascade of ongoing inflammation mediated by peripheral and central immune effector cells, viral neurotoxins, pro-inflammatory cellular metabolites, and by a reduction in normal levels of trophic factors in the central nervous system. Steps in this inflammatory cascade may provide useful targets for adjunctive therapies for HAND. There is a similar need for adjunctive therapies for HIV-associated peripheral neuropathy. This chapter discusses the design of clinical trials for these therapies as well as particular targets and drugs.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.